@article{b805b8c64c564a09b580201edfaaaaaa,
title = "A role for EMT in CD73 regulation in breast cancer",
abstract = "CD73 is an emerging target in cancer due to its role in generating adenosine, a potent immunosuppressor. We found that SNAI1, a driver of epithelial-to-mesenchymal transition (EMT), upregulates CD73 in triple negative breast cancer cells. Here, we discuss the relevance of improving CD73-based therapy by combining with inhibitors of EMT.",
keywords = "Humans, Epithelial-Mesenchymal Transition, Triple Negative Breast Neoplasms/genetics, Adenosine",
author = "Meriem Hasmim and Guy Berchem and Bassam Janji",
note = "Funding This work was supported by grants from FNRS-Televie (7.4579.20-CD73), Luxembourg National Research Fund (BRIDGES2020/BM/15412275/ SMART-COMBO; BRIDGES2021/BM/16358198/TRICK-ALDH and INTER/EUROSTARS21/16896480/C2I), Fondation Recherche Cancer et Sang, Luxembourg (INCOM BIOM), Kriibskrank Kanner Foundation; Luxembourg (Neuroimmunotherapy II-2019) and Stiftelsen Cancera (2022; Fonds De La Recherche Scientifique – FNRS). {\textcopyright} 2022 The Author(s). Published with license by Taylor & Francis Group, LLC.",
year = "2022",
month = nov,
day = "30",
doi = "10.1080/2162402X.2022.2152636",
language = "English",
volume = "11",
journal = "OncoImmunology",
issn = "2162-4011",
publisher = "Landes Bioscience",
number = "1",
}